Emcure Pharmaceuticals (NSE:EMCURE) Cash Flow for Dividends: ₹0 Mil (TTM As of Mar. 2026)


NSE:EMCURE Emcure Pharmaceuticals Ltd NSE:EMCURE
41 GF Score
Price ₹1,856.50
! 5 Warning Signs
View Full Analysis

What is Emcure Pharmaceuticals Cash Flow for Dividends?

Emcure Pharmaceuticals NSE:EMCURE +1.40% 41 Cash Flow for Dividends is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:EMCURE with a GF Score™ of 41/100. The stock has 5 warning signs investors should review.

Emcure Pharmaceuticals's cash flow for dividends for the three months ended in Mar. 2026 was ₹0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Emcure Pharmaceuticals's annual payment of dividends declined from Mar. 2024 (₹-543 Mil) to Mar. 2025 (₹0 Mil) but then increased from Mar. 2025 (₹0 Mil) to Mar. 2026 (₹-569 Mil).

Emcure Pharmaceuticals Cash Flow for Dividends Related Terms

Emcure Pharmaceuticals Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Emcure Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emcure Pharmaceuticals Cash Flow for Dividends Chart

Emcure Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash Flow for Dividends
Get a 7-Day Free Trial -542.55 -361.70 -542.55 0.00 -568.53

Emcure Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:EMCURE
41GF Score
Emcure Pharmaceuticals Ltd NSE:EMCURE
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emcure Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of ₹0 Mil mean?
Emcure Pharmaceuticals (NSE:EMCURE) has a Cash Flow for Dividends of ₹0 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Emcure Pharmaceuticals and its competitors.
Is Emcure Pharmaceuticals' Cash Flow for Dividends too high?
Emcure Pharmaceuticals' current Cash Flow for Dividends is ₹0 Mil. Overall, Emcure Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' Cash Flow for Dividends compare to ZTS and UTHR?
Emcure Pharmaceuticals' Cash Flow for Dividends of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Emcure Pharmaceuticals and its competitors. Emcure Pharmaceuticals's current Cash Flow for Dividends is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current Cash Flow for Dividends of ₹0 Mil. The current Cash Flow for Dividends is ₹0 Mil. Emcure Pharmaceuticals' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current Cash Flow for Dividends is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emcure Pharmaceuticals Business Description

Other Exchanges 544210:India
Address Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune, MH, IND, 411 057
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
41GF Score

Get the complete analysis for NSE:EMCURE

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,856.50
Price